Rhiannon B Werder1, Vivian Zhang1, Jason P Lynch2, Natale Snape3, John W Upham4, Kirsten Spann5, Simon Phipps6. 1. School of Biomedical Sciences, University of Queensland, Brisbane, Australia; QIMR Berghofer Medical Research Institute, Brisbane, Australia. 2. School of Biomedical Sciences, University of Queensland, Brisbane, Australia. 3. School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia. 4. Diamantina Institute, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia; Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, Australia. 5. School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia; Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, Australia. 6. School of Biomedical Sciences, University of Queensland, Brisbane, Australia; Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, Australia; QIMR Berghofer Medical Research Institute, Brisbane, Australia. Electronic address: simon.phipps@qimrberghofer.edu.au.
Abstract
BACKGROUND: Rhinovirus infection triggers acute asthma exacerbations. IL-33 is an instructive cytokine of type 2 inflammation whose expression is associated with viral load during experimental rhinovirus infection of asthmatic patients. OBJECTIVE: We sought to determine whether anti-IL-33 therapy is effective during disease progression, established disease, or viral exacerbation using a preclinical model of chronic asthma and in vitro human primary airway epithelial cells (AECs). METHODS: Mice were exposed to pneumonia virus of mice and cockroach extract in early and later life and then challenged with rhinovirus to model disease onset, progression, and chronicity. Interventions included anti-IL-33 or dexamethasone at various stages of disease. AECs were obtained from asthmatic patients and healthy subjects and treated with anti-IL-33 after rhinovirus infection. RESULTS: Anti-IL-33 decreased type 2 inflammation in all phases of disease; however, the ability to prevent airway smooth muscle growth was lost after the progression phase. After the chronic phase, IL-33 levels were persistently high, and rhinovirus challenge exacerbated the type 2 inflammatory response. Treatment with anti-IL-33 or dexamethasone diminished exacerbation severity, and anti-IL-33, but not dexamethasone, promoted antiviral interferon expression and decreased viral load. Rhinovirus replication was higher and IFN-λ levels were lower in AECs from asthmatic patients compared with those from healthy subjects. Anti-IL-33 decreased rhinovirus replication and increased IFN-λ levels at the gene and protein levels. CONCLUSION: Anti-IL-33 or dexamethasone suppressed the magnitude of type 2 inflammation during a rhinovirus-induced acute exacerbation; however, only anti-IL-33 boosted antiviral immunity and decreased viral replication. The latter phenotype was replicated in rhinovirus-infected human AECs, suggesting that anti-IL-33 therapy has the additional benefit of enhancing host defense.
BACKGROUND:Rhinovirus infection triggers acute asthma exacerbations. IL-33 is an instructive cytokine of type 2 inflammation whose expression is associated with viral load during experimental rhinovirus infection of asthmatic patients. OBJECTIVE: We sought to determine whether anti-IL-33 therapy is effective during disease progression, established disease, or viral exacerbation using a preclinical model of chronic asthma and in vitro human primary airway epithelial cells (AECs). METHODS:Mice were exposed to pneumonia virus of mice and cockroach extract in early and later life and then challenged with rhinovirus to model disease onset, progression, and chronicity. Interventions included anti-IL-33 or dexamethasone at various stages of disease. AECs were obtained from asthmatic patients and healthy subjects and treated with anti-IL-33 after rhinovirus infection. RESULTS: Anti-IL-33 decreased type 2 inflammation in all phases of disease; however, the ability to prevent airway smooth muscle growth was lost after the progression phase. After the chronic phase, IL-33 levels were persistently high, and rhinovirus challenge exacerbated the type 2 inflammatory response. Treatment with anti-IL-33 or dexamethasone diminished exacerbation severity, and anti-IL-33, but not dexamethasone, promoted antiviral interferon expression and decreased viral load. Rhinovirus replication was higher and IFN-λ levels were lower in AECs from asthmatic patients compared with those from healthy subjects. Anti-IL-33 decreased rhinovirus replication and increased IFN-λ levels at the gene and protein levels. CONCLUSION: Anti-IL-33 or dexamethasone suppressed the magnitude of type 2 inflammation during a rhinovirus-induced acute exacerbation; however, only anti-IL-33 boosted antiviral immunity and decreased viral replication. The latter phenotype was replicated in rhinovirus-infectedhuman AECs, suggesting that anti-IL-33 therapy has the additional benefit of enhancing host defense.
Authors: Lyndsey M Muehling; Peter W Heymann; Paul W Wright; Jacob D Eccles; Rachana Agrawal; Holliday T Carper; Deborah D Murphy; Lisa J Workman; Carolyn R Word; Sarah J Ratcliffe; Brian J Capaldo; Thomas A E Platts-Mills; Ronald B Turner; William W Kwok; Judith A Woodfolk Journal: J Allergy Clin Immunol Date: 2020-04-19 Impact factor: 10.793
Authors: Jenna M Magat; Joanna L Thomas; Justin P Dumouchel; Fiona Murray; Willis X Li; Jinghong Li Journal: J Immunol Date: 2020-01-27 Impact factor: 5.422
Authors: Lisa M Jurak; Yang Xi; Megan Landgraf; Melanie L Carroll; Liisa Murray; John W Upham Journal: Front Immunol Date: 2018-08-16 Impact factor: 7.561
Authors: Cecilia Andersson; Sara J Bonvini; Peter Horvath; Eduardo Marquez; Imran Satia; Paul Kirkham; Florence Schleich; Marco Idzko; Reinoud Gosens; Jose Luis Lopez-Campos; Apostolos Bossios; Omar Usmani; Antonio Spanevello; Ian M Adcock; Alexander G Mathioudakis Journal: ERJ Open Res Date: 2018-03-13